Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
  • C12N1/14—Fungi; Culture media therefor
  • C12N1/16—Yeasts; Culture media therefor
  • C12N1/18—Baker's yeast; Brewer's yeast
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/66—Microorganisms or materials therefrom
  • A61K35/74—Bacteria
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/66—Microorganisms or materials therefrom
  • A61K35/74—Bacteria
  • A61K35/741—Probiotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
  • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
  • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides

Definitions

• the present invention relates to the production and secretion of biologically active polypeptide(s) or protein(s) by gut microflora, methods of delivering same and methods of controlling the production and secretion of said biologically active polypeptide(s) or protein(s).
• the present invention is of particular use in the development of new immunotherapies and especially for the treatment of inflammatory gut diseases.
• the microbial community in the human large intestine consists of a diverse range of bacteria that are predominantly obligate anaerobes. These bacteria act together to degrade dietary substrates that reach the colon (including insulin, fructo- oligosaccharides and resistant starch), producing a range of products that are important for human health and disease.
• the mucosal immune response can be influenced by manipulation of the normal resident bacterial flora.
• This flora possesses a large variety of biological and immunomodulatory properties that can, directly or indirectly, influence the development and function of the mucosal immune system.
• Chronic disorders of the gut for example inflammatory bowel disease (IBD) which includes the disorders Crohn's disease and ulcerative colitis, affect a significant proportion of the population in developed countries. Animal models of mucosal inflammation have been used to try and determine the immune mechanisms involved in the pathogenesis of these diseases.
• Chronic colitis develops spontaneously in interleukin (IL) 2 ⁇ ' ⁇ and IL10 " ' " mice both of which are used as models of IBD.
• IL interleukin
• IBD immune response genes
• Current treatment of IBD is restricted to antiinflammatory and immunosuppressive drug therapies including recombinant IL10 and antibodies to tumour necrosis factor- ⁇ (TN F- ⁇ ).
• these therapies are not curative and may cause adverse side effects such as toxicity and immunosuppression. Therefore, there is a need for a more targeted and controlled form of immunotherapy.
• commensal, or bacteria that occur naturally in the alimentary canal such as Lactobacillus spp. and Streptococcus spp. to treat intestinal inflammation and certain forms of IBD in humans (Shanahan 2001), however these results have limited evidence of success and inconsistent efficacy.
• L lactis is not able to colonise the gut due to the inability of the organism to bind to the gut epithelium and/or its nutritional dependence on the provision of amino acids and peptides which are unavailable in vivo. Accordingly any in vivo treatment or therapy would require repeated dosing to the appropriate site with the modified organism.
• Another biosafety concern and disadvantage of the use of this particular aerobic bacterium is that it could survive outside of the host/patient for sufficient time to be transmitted to others.
• a yet further disadvantage of the prior art systems is that there is no means of controlling the constitutive expression of the immunologically active interleukin molecules and these active molecules themselves when overproduced, can have adverse effects. Accordingly the prior art genetically modified probiotic systems lack control and regulation of the activity of probiotic bacteria after administration. This represents a serious safety issue for human therapy.
• a gut commensal bacterium modified to express one or more biologically active polypeptides or protiens, the bacterium further comprising a promoter which is induced in response to the presence of a dietry factor and which regulates the expression of said biologically active polypeptide or protien.
• An operon may be defined as a functional unit consisting of a promoter, an operator and a number of structural genes.
• An example is the xylanase operon.
• the structural genes commonly code for several functionally related enzymes, and although they are transcribed as one (polycistronic) mRNA, each has its separate translation initiation site.
• the operator region acts as a controlling element in switching on or off the synthesis of mRNA.
• the xylanase operon is activated in the presence of xylan.
• the promoter is constitutive and more preferably is the xylanase promoter.
• the expression of the one or more biologically active polypeptides or protiens is controlled by the presence of xylan in the diet.
• the bacteria can therefore be said to comprise a xylan-inducible regulatory element.
• Xylan is a water-soluble, gummy polysaccharide found in plant cell walls and yielding xylose upon hydrolysis. It is therefore a common dietary factor or component, accordingly the inclusion or exclusion of xylan in the diet controls the expression of the biologically active polypeptide or protien.
• the modified bacteria of the present invention therefore advantageously provide an easily controllable expression system avoiding repeated invasive dosing of an individual since the modified bacteria of the present invention are also able to colonise the gut whilst concomitantly minimising any adverse side-effects.
• the bacterium is obligate anaerobe and more preferably still said bacterium is either Bacteroides ovatus or Prevotella.
• the bacterium in non-pathogenic to man.
• Bioly active refers to the ability to perform a biological function.
• the biologically active polypeptide or protein used in the present invention can be either homologous to the bacterium or heterologous thereto, derived from either eukaryotic or prokaryotic or viral sources.
• polypeptides and proteins used in the present invention preferably include insulin, growth hormone, prolactin, calcitonin, luteinising hormone, parathyroid hormone, somatostatin, thyroid stimulating hormone, vasoactive intestinal polypeptide, trefoil factors, cell and tissue repair factors, transforming growth factor ⁇ , keratinocyte growth factor, a structural group 1 cytokine adopting an antiparallel 4 ⁇ helical bundle structure such as IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-11 , IL-12, IL-13, GM-CSF, M-CSF, SCF, IFN- ⁇ , EPO 1 G-CSF, LIF, OSM, CNTF, GH, PRL or !FN ⁇ / ⁇ , a structural group 2 cytokine which are often cell-surface associated, form symmetric homotrimers and the subunits take up the conformation of ⁇ -jelly roll described for certain
• the biologically active polypeptide can be a receptor or antagonist for biologically active polypeptides as defined above.
• the bacterium expresses the biologically active polypeptide or protein and the antigen from nucleic acid contained within it.
• the nucleic acid may comprise one or more nucleic acid constructs in which nucleic acid encoding the biologically active polypeptide and nucleic acid encoding the antigen are under control of appropriate regulatory sequences for expression in the bacterium.
• the bacterium may also express the biologically active polypeptide or protein as a vaccine.
• the bacterium of the present invention may be modified to express a plurality of biologically active polypeptides or proteins.
• a pharmaceutical comprising a gut commensal bacterium modified to express one or more biologically active polypeptides or protiens, the bacterium further comprising a promoter which is induced in response to the presence of a dietry factor and which regulates the expression of said biologically active polypeptide or protien.
• the pharmaceutical is provided as a composition in a physiologically acceptable carrier, diluent or excipient.
• the pharmaceutical comprises any one or more of the features hereinbefore recited.
• a gut commensal bacterium modified to express one or more biologically active polypeptides or protiens, the bacterium further comprising a promoter which is induced in response to the presence of a dietry factor and which regulates the expression of said biologically active polypeptide or protien, in the manufacture of a medicament for the treatment of chronic infammatory bowel disease.
• the use further comprises any one or more of the features hereinbefore recited.
• a method of delivering one or more biologically active polypeptides or proteins or antigens or enzymes or vaccine which comprises administering to a subject a gut commensal bacterium which expresses one or more of said biologically active agents expression of which is under control of a promoter which is activated in the presence of a dietry factor.
• bacterium expresses more than one biologically active polypeptide or protein or antigen or enzyme or vaccine or a combination thereof.
• the method comprises the administration of a mixture of bacteria expressing a variety of biologically active polypeptides or proteins or antigens or enzymes or vaccines or a combination thereof.
• bacteria capable of expressing IL2 and bacteria capable of expressing IL12 and/or IL9 and optionally bacteria capable of expressing a cell and tissue repair factor are provided, for example and without limitation, bacteria capable of expressing IL2 and bacteria capable of expressing IL12 and/or IL9 and optionally bacteria capable of expressing a cell and tissue repair factor.
• the method includes any one or more of the features herein before described.
• Bacteroides ovatus is a major commensal colonic Gram-negative bacterium in humans and rodents for which cloning systems are available that allow the introduction of foreign DNA into the organism and integration into the genome (Tancula et al. 1992). This organism is also one of only a few that are able to degrade the polysaccharide xylan.
• Our results demonstrate that ⁇ . ovatus can be induced to produce biologically active MulL2 in response to xylan.
• a method of treating chronic inflammation of the gut comprising administering to an individual suffering from such a condition a pharmaceutically effective amount of a gut commensal bacterium modified to express one or more biologically active polypeptides or protiens, the bacterium further comprising a promoter which is induced in response to the presence of a dietry factor and which regulates the expression of said biologically active polypeptide or protien.
• bacteria of the invention offers a means of delivering immunomodulatory factors, such as cytokines, and other biologically active molecules directly to the site action to treat chronic inflammation of the gut.
• immunomodulatory factors such as cytokines
• other biologically active molecules directly to the site action to treat chronic inflammation of the gut.
• the advantages of this unique form of therapeutic delivery is that it is a convenient and simple means of delivering biologically active proteins directly to their site of action, avoiding the inconvenience and systemic exposure associated with parenteral therapy
• Figure 1 shows a schematic construction of plasmid pBOMulL2.
• Figure 2 shows a bar chart of levels of MulL2 in cell lysates (CL) and culture supematants (SN) of S. ovatus BOMulL2, S. ovatus BOMulL2-S and control strains (V975 and BT2) grown with xylan for 24 h (+X) or without xylan.
• Figure 3 shows the result of a bioassay of MulL2 in culture supematants of B. ovatus BOMulL2-S grown with xylan.
• Figure 4 shows a gel of increased expression of MulL2 mRNA in response to xylan determined by RT-PCR with test (BOMulL2 and BOMulL2-S) or control strains (V975 and BT2) of B. ovatus grown for 24 h in RGM without xylan followed by 1 h with xylan.
• Figure 5 shows the construct map of B ovatus expressing either human TGF/? or KGF.
• Figure 6 A shows the production of human cytokines by ⁇ . ovatus expressing human TGF/? in response to xylan and
• Figure 6 B shows the production of human cytokines by B. ovatus expressing human KFG in response to xylan.
• E coli DH5 ⁇ and J53/R751 were grown in LB medium. Cultures of E. coli J53/R751 were supplemented with 200 ⁇ g trimethoprim ml "1 . B. ovatus V975 was grown anaerobically at 37 0 C in brain heart infusion (BHI) broth supplemented with 10 ⁇ g haemin ml "1 or in routine growth medium (RGM) prepared as described by Hespeil et al. (1987) and supplemented with 0.1% (w/v) glucose.
• BHI brain heart infusion
• RGM routine growth medium
• a hot water-soluble fraction of oatspelt xylan was prepared by the method of Hespeil and O'Bryan (1992) and added to media at a concentration of 0.2% (w/v).
• Transfer of plasmids to B. ovatus from E. coli J53/R751 was carried out by conjugation as described by Valentine et al. (1992).
• pBT2 Teancula et al. 1992
• R ovatus transconjugants were selected on BHI- haemin agar containing 200 ⁇ g gentamicin ml "1 and 5 ⁇ g tetracycline ml "1 . Transconjugants were subsequently grown in medium containing 1 ⁇ g tetracycline ml "1 . E. coli was transformed by the method of Hanahan (1983). General DNA manipulations were carried out as described by Sambrook et al. (1990).
• the MulL.2 gene was PCR-amplified from cDNA cloned in pUC13 using primers MulL2F1 (GCGCATATGGCACCCACTTC AAGCTCCAC;SEQ ID NO:1 Nde ⁇ site in bold) and MulL2R1 (GCGGGATCCTT ATTGAGGGCTTGTTGAGATGATG; SEQ ID NO:2 BamHI site in bold).
• MulL2F1 GCGCATATGGCACCCACTTC AAGCTCCAC;SEQ ID NO:1 Nde ⁇ site in bold
• MulL2R1 GCGGGATCCTT ATTGAGGGCTTGTTGAGATGATG; SEQ ID NO:2 BamHI site in bold.
• ovatus xylanase operon encompassing the 3' half of the orf gene and region between this gene and the xyl gene was amplified from plasmid pOX1 (Whitehead and Hespeil 1990) using primers ORFF1 (GCGGGATCCATGGAGCA TGAATGCGTCA; SEQ ID NO:3 SamHI site in bold) and ORFR1 (CATATGTTA TATTTTTGAGTAATAAACATTCTAC; SEQ ID NO:4 Nde ⁇ site in bold).
• the MulL2 and ORF PCR products were cloned into pGEM-T (Promega) to create plasmids pGEM-MulL2 and pGEM-ORF respectively.
• MuIL2 was removed from pGEM-MulL2 with ⁇ /cfel and ligated into ⁇ /cfel-digested pGEM-ORF to create pORF-MulL2.
• the insert was sequenced to verify the construct.
• the ORF-MulL2 construct was removed from pORF-MulL2 by SamHI digestion and cloned into the SamHI site of pBT2 to create pBOMuIL2. This plasmid was transferred into B. ovatus by conjugation and integration of the plasmid into the genome of transconjugants was confirmed by PCR.
• ovatus strain BOMulL2-S was constructed in the same way as strain BOMuIL2 except that the MulL2 gene was PCR-amplified using primers BFTSIGIL2F (GACATATGAAGAATGTAAAGTTACTTTTAA TGCTAGGAACCGCGGCATTATTAGCTGCAGCACCCACTTCAAGCTCCAC; SEQ ID NO:5 signal sequence coding region is underlined, Nde ⁇ site in bold) and MuIL2R1.
• BFTSIGIL2F GACATATGAAGAATGTAAAGTTACTTTTAA TGCTAGGAACCGCGGCATTATTAGCTGCAGCACCCACTTCAAGCTCCAC; SEQ ID NO:5 signal sequence coding region is underlined, Nde ⁇ site in bold
• MuIL2R1 MuIL2R1.
• Control strain BT2 The control strain containing pBT2 without the MulL2 gene was constructed as follows. The same portion of the orf gene as used above was PCR amplified with primers ORFF1 and ORFR2 (GGATCCTTATATTTTTGAGTAAT AAACATTCTAC; SEQ ID NO:6 BamHI site in bold) and cloned into pGEM-T to create pGEM-ORFB. The insert was removed with SamHI and cloned into the SamHI site of pBT2 to create pBT-ORF. This plasmid was transferred into S. ovatus as described above.
• RT-PCR was performed using the AccessQuickTM RT-PCR System (Promega) and primers for the orf-Muil2 fusion (CCGATGGTACCTGCCATTAAA (SEQ ID NO:7) and
• CTGTGCTTCCGCTGAGG SEQ ID NO:8 or the gyrA gene (CTCCATGTCGG
• TCATCGTTTC SEQ ID NO:9
• CAAAGGATAACGCATTGCCCA SEQ ID NO:9
• the MuIL2 gene (minus native signal sequence) and 3' portion of the orf gene of the xylanase operon were PCR-amplified and ligated in pGEM-T to give plasmid pORF-MulL2.
• An ATG start codon was positioned before the sequence encoding the mature MulL2 as part of an Nde ⁇ site. This ensured translation of the protein.
• ovatus kan, kanamycin resistance for selection in E. col ⁇ , oriV, origin of replication
• repA, repB, repC encode replication functions and mob is required for mobilization from E. coli to B. ovatus.
• the pBOMulL2 plasmid (Fig. 1) was then successfully transferred to B. ovatus V975.
• the MulL2-secreting strain, B. ovatus BOMulL2-S was constructed in the same way except that the forward primer used to PCR-amplify the MulL2 gene, contained the sequence coding for the B. fragilis enterotoxin secretion signal sequence.
• a control strain, ⁇ . ovatus BT2 was also constructed by cloning only the orf gene into pBT2. Successful construction of the MulL2 and MulL2-S expression strains, and BT2 control strain was confirmed by PCR and nucleotide sequencing (data not shown).
• mice Since the utility of using ⁇ .ovafc/s-Mull_2 to treat IL2 ';" mice is dependent upon demonstrating that it can colonise the mouse colon, we determined if B.ovatus- MulL2 could colonise the colon of wildtype mice. Wildtype, specific pathogen free (SPF), C57BL/6 mice, maintained on a conventional diet (containing xylan), were infected with a single inoculum of ⁇ 10 10 cfu ⁇ .ovafus-MulL2 by oral gavage.
• SPPF specific pathogen free
• Colonisation was evaluated 7, 14, 21 and 28 days later by culturing faecal pellets under anaerobic conditions in the presence of antibiotics permissive for the growth of all Bacteroides sp., or for the growth of ⁇ .ovafus-MulL2 alone.
• identity of ⁇ .ovafus-Mull_2 in faecal cultures will be more extensively verified by colony filter hybridisation techniques using a full-length murine IL2 cDNA clone as a probe.
• mice No. 1 and 4 contained no B. ovaft/s-Mull_2 consistent with colonisation failure.
• a concern in using commensal bacteria in immunotherapy protocols for IBD is that the chosen bacteria may, in immunocompromised animals and patients, be "pathogenic" and promote, amplify or sustain intestinal inflammation.
• Bacteroides, and in particular S. fragilis and B. vulgatis have been associated with the development of intestinal inflammation in experimental animal models of IBD and in IBD patients.
• One study has also identified increased titres of IgA and IgG antibodies reactive with antigens of B. ovatus in the sera of IBD patients 5 .
• this was a cause of intestinal inflammation, or was secondary to Bacteroides and other commensal bacteria gaining entry to the systemic circulation and triggering immune responses as a result of damage to the epithelial barrier.
• ovatus BOMulL2 B. ovatus BOMulL2-S and control strains (V975 and BT2) grown with xylan for 24 h (+X) or without xylan.
• BOMulL2-S was also grown without xylan for 16 h followed by 8 h with xylan (+X8).
• Test and control strains of ⁇ . ovatus were grown in RGM with or without xylan.
• Cells were harvested and lysed and the amount of MulL2 in lysates and culture supernatants determined by ELISA.
• MulL2 was quantified by comparison to a dilution series of recombinant MulL2. Data points are mean +/- standard error.
• MulL2 was detected in the cell lysate of B. ovatus BOMulL2 grown with xylan (539.5 pg ml "1 ) and at a lower concentration (44.2 pg ml "1 ) in culture supernatants.
• For strain BOMuIL2-S 19.3 times more MulL2 (849.9 pg ml-1) was detected in the supernatant of the culture grown in the presence of xylan compared to BOMulL2.
• a lower concentration of MulL2 (184.3 pg ml "1 ) was detected in the cell lysate of BOMulL2-S.
• MulL2 was not detected in cell lysates or culture supernatants from the two control strains or from ⁇ . ovatus BOMulL2 or BOMulL2-S cultured in the absence of xylan.
• FIG. 3 shows the results of a bioassay of MulL2 in culture supematants of B. ovatus BOMulL2-S grown with xylan. Proliferation of CTLL-2 cells was measured by the uptake of [ 3 H]thymidine following incubation with doubling dilutions of:B, S. ovatus BOMulL2-S supernatant alone; D, B. ovatus BOMulL2-S supernatant with anti-MulL2 antibody. MulL2 was quantified by comparison to a dilution series of recombinant MuI L2.
• RT-PCR was performed, ⁇ . ovatus BOMulL2 and BOMulL2-S were grown in RGM with glucose for 16 h and a cell sample taken. Xylan was then added and samples taken after 1 h. Samples from cultures of control strains were also taken following xylan induction. Total RNA was extracted from cells and RT-PCR performed with primers specific for the orf- MulL2 construct and for gyrA, a commonly used constitutively expressed control gene. A basal level of transcription could be detected in both BOMulL2 and BOMulL2-S strains before addition of xylan that increased 1 h after xylan addition (Fig. 4).
• Figure 4 shows increased expression of MulL2 mRNA in response to xylan as determined by RT-PCR.
• Test BOMulL2 and BOMulL2-S
• control strains V975 and BT2
• V975 and BT2 control strains
• Xylan was then added and incubation continued for 1h.
• Cells were harvested, total RNA extracted and RT-PCR performed to detect MulL2 and MulL2-S transcripts.
• gyrA was used as a positive control.
• MulL2 gene transcription was not detected in the two control strains. Although transcription was detected in the MuIL2-producing strains before the addition of xylan, it was not possible to detect the MulL2 protein in cell lysates or culture supernatants (Fig. 2).
• the system of the present invention also provides for the control or regulation in vivo by dietary intake of xylan. This feature of the invention has the advantage over other inducible systems in that xylan remains undigested as it passes through the gut to the colon and is only degraded in the colon by the action of microbial enzymes.
• MulL2 production was at a level too low ( ⁇ 20 pg ml "1 ) for detection by ELISA in cell lysates or culture supernatants.
• the inability to detect any MulL2 in xylan-induced cultures of B. ovatus pBOMulL2 following withdrawal of xylan demonstrated the stringency of the xylanase operon and a need for the continued presence of xylan for MulL2 production (data not shown).
• the levels of MulL2 produced and secreted by S. ovatus are low, but within physiological range.
• mice were administered a single dose of recombinant strain of ⁇ . ovatus expressing the murine IL2 gene by oral gavage (10 8 cfu in PBS) and 3 and 7 days (T) later the stools were cultured for the presence of all native Bacteroides sp. and the recombinant B. ovatus using selective culture conditions and use of antibiotics. Bacteria colonies (cfu) were quantitated after 24 h.
• mice Colonisation of mice by recombinant strains of B. ovatus
• FIG. 5 shows the construct map of B ovatus expressing either human TGF ⁇ or KGF.
• Recombinant strains of B.ovatus expressing genes encoding either human KGF (BoHuKGF) or TGF ⁇ (BoHuTGF) or, control strains (BoBTS) that contain no heterologous genes were cultured in complete media alone (Media) or in media containing xylan for 8 or 24 h prior to assaying culture supernatants for TGF ⁇ and KGF by ELISA.
• Some cultures of recombinant B.ovatus were cultured with xylan for 8 h prior to removing media and culturing for a further 24 h in complete media alone (BoHuKGF/TGF ⁇ xylan).
• Figure 6A shows the graphs of the average amounts ( ⁇ SEM) of cytokine present in the culture supernatants detected in 3 independent experiments with B.ovatus expressing the gene encoding human KGF TGF ⁇ (BoHuTGF).
• Figure 6B shows the same experimental data from B.ovatus expressing the gene encoding human KFG (BoHuKGF).
• the ability to engineer commensal bacteria to produce immunomodulatory molecules under the control of dietary factors offers the potential of providing a more measured, specific arid controlled therapy for chronic gut disorders such as IBD.
• This approach can be used to deliver a variety of biologically relevant molecules, including cytokines, enzymes and vaccines, with applications in treatment and prevention of a variety of disorders.
• Inflammatory bowel disease immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 120, 622-635.
• Tancula E., Feldhaus, M.J., Bedzyk, L.A. and Salyers, A.A. (1992) Location and characterization of genes involved in binding of starch to the surface of Bacteroides thetaiotaomicron. Journal of Bacteriology 174, 5609-5616.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Mycology (AREA)
• Chemical & Material Sciences (AREA)
• Microbiology (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Organic Chemistry (AREA)
• Epidemiology (AREA)
• Molecular Biology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biotechnology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Zoology (AREA)
• Wood Science & Technology (AREA)
• General Chemical & Material Sciences (AREA)
• Genetics & Genomics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Biomedical Technology (AREA)
• Virology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Botany (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Biochemistry (AREA)
• General Engineering & Computer Science (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (2)

Family

ID=34259652

Family Applications (1)

Country Status (10)

Cited By (11)

Families Citing this family (7)

Family Cites Families (4)

• 2005
  • 2005-01-25 GB GBGB0501540.9A patent/GB0501540D0/en not_active Ceased
• 2006
  • 2006-01-24 US US11/814,739 patent/US7988961B2/en not_active Expired - Fee Related
  • 2006-01-24 AT AT06701043T patent/ATE483811T1/de not_active IP Right Cessation
  • 2006-01-24 EP EP06701043A patent/EP1841875B1/en not_active Not-in-force
  • 2006-01-24 JP JP2007551749A patent/JP4989490B2/ja not_active Expired - Fee Related
  • 2006-01-24 KR KR1020077019503A patent/KR101291960B1/ko not_active Expired - Fee Related
  • 2006-01-24 DE DE602006017331T patent/DE602006017331D1/de active Active
  • 2006-01-24 WO PCT/GB2006/000222 patent/WO2006079790A2/en not_active Ceased
  • 2006-01-24 CA CA2640343A patent/CA2640343C/en not_active Expired - Fee Related
  • 2006-01-24 ES ES06701043T patent/ES2353721T3/es active Active

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events